Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$36.45 - $47.7 $244,178 - $319,542
-6,699 Reduced 3.1%
209,194 $9.97 Million
Q1 2024

May 14, 2024

BUY
$42.03 - $53.55 $9.07 Million - $11.6 Million
215,893 New
215,893 $9.36 Million
Q1 2023

May 11, 2023

SELL
$33.58 - $41.2 $1.31 Million - $1.61 Million
-39,060 Reduced 12.83%
265,330 $9.48 Million
Q4 2022

Feb 13, 2023

BUY
$37.12 - $46.52 $11.1 Million - $13.9 Million
297,973 Added 4643.49%
304,390 $11.5 Million
Q3 2022

Nov 10, 2022

SELL
$36.54 - $48.66 $1.14 Million - $1.52 Million
-31,173 Reduced 82.93%
6,417 $284,000
Q2 2022

Aug 19, 2022

BUY
$31.71 - $43.0 $1.19 Million - $1.62 Million
37,590 New
37,590 $1.39 Million
Q1 2022

May 13, 2022

SELL
$29.88 - $37.04 $591,265 - $732,947
-19,788 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$25.61 - $35.1 $297,460 - $407,686
11,615 Added 142.11%
19,788 $602,000
Q3 2021

Nov 15, 2021

BUY
$33.54 - $40.55 $274,122 - $331,415
8,173 New
8,173 $274,000
Q4 2020

Feb 16, 2021

SELL
$45.3 - $60.27 $1.2 Million - $1.6 Million
-26,507 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$47.45 - $62.95 $1.26 Million - $1.67 Million
26,507 New
26,507 $1.26 Million
Q2 2020

Aug 14, 2020

SELL
$46.85 - $61.05 $278,007 - $362,270
-5,934 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$41.6 - $63.4 $53,248 - $81,152
1,280 Added 27.5%
5,934 $281,000
Q4 2019

Feb 14, 2020

BUY
$53.85 - $65.27 $250,617 - $303,766
4,654 New
4,654 $281,000
Q2 2019

Aug 14, 2019

SELL
$62.09 - $86.14 $3.94 Million - $5.47 Million
-63,522 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$52.92 - $81.17 $3.07 Million - $4.71 Million
58,022 Added 1054.95%
63,522 $5.16 Million
Q4 2018

Feb 14, 2019

BUY
$43.37 - $59.54 $238,535 - $327,470
5,500 New
5,500 $297,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.35B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.